Catalog No.
RHJ14404
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400
Target
B- and T-lymphocyte attenuator, BTLA, CD272, B- and T-lymphocyte-associated protein
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q7Z6A9
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3V22
B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer., PMID:40463377
Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study., PMID:40276504
Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients., PMID:39768154
Association between peripheral activated naive and double negative 2 B-cell subsets and clinical parameters in lupus nephritis patients., PMID:39592449
The Immune Checkpoint BTLA in Oral Cancer: Expression Analysis and Its Correlation to Other Immune Modulators., PMID:38928307
Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma., PMID:38733770
BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion., PMID:38418488
Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma., PMID:38244072
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors., PMID:37230538
BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia., PMID:37041226
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM., PMID:36081508
Role of BTLA/HVEM network in development of gastric cancer., PMID:35914980
Targeting the HVEM protein using a fragment of glycoprotein D to inhibit formation of the BTLA/HVEM complex., PMID:35325694
Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery., PMID:34205742
BTLA Expression and Function Are Impaired on SLE B Cells., PMID:33968071
BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia., PMID:33917094
Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies., PMID:33238640
Correlations of the expression of γδ T cells and their co-stimulatory molecules TIGIT, PD-1, ICOS and BTLA with PR and PIBF in the peripheral blood and decidual tissues of women with unexplained recurrent spontaneous abortion., PMID:33017473
PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2., PMID:32437509
The Co-inhibitor BTLA Is Functional in ANCA-Associated Vasculitis and Suppresses Th17 Cells., PMID:31921121
BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes., PMID:31753019
CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro., PMID:31332464
Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy., PMID:31189114
Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity., PMID:30990953
Expression and clinical significance of B and T lymphocyte attenuator on CD4+ and CD8+ T cells from patients with pulmonary tuberculosis., PMID:30971546
Expression of B and T lymphocyte attenuator, retinoid-related orphan receptor gamma-isoform-t and interleukin 7 in psoriasis vulgaris., PMID:30671936
Not All Immune Checkpoints Are Created Equal., PMID:30233564
PD-1 has a unique capacity to inhibit allergen-specific human CD4+ T cell responses., PMID:30201974
BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints., PMID:29353075
A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator., PMID:29061848
Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade., PMID:28882621
Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses., PMID:28594868
Expression of B and T Lymphocyte Attenuator in Patients with Severe Community-Acquired Pneumonia and the Effect of Steroid Therapy in a Mouse Model., PMID:28164546
B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity., PMID:27412504
Chronic HIV-1 Infection Induces B-Cell Dysfunction That Is Incompletely Resolved by Long-Term Antiretroviral Therapy., PMID:26914910
A Preliminary Comparative Assessment of the Role of CD8+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis., PMID:26881265
Decreased B and T lymphocyte attenuator in Behcet's disease may trigger abnormal Th17 and Th1 immune responses., PMID:26841832
Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents., PMID:26287276
BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine., PMID:26277622
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors., PMID:26253731
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele., PMID:26212219
Increased Heterologous Protein Expression in Drosophila S2 Cells for Massive Production of Immune Ligands/Receptors and Structural Analysis of Human HVEM., PMID:26202493
A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy., PMID:25267972
[The decline in lung function is associated with a decrease in the number of BTLA⁺ lymphocytes and regulatory T cells in patients with rheumatism]., PMID:24909289
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer., PMID:23756627
The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells., PMID:23692853
B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function., PMID:23532637
Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity., PMID:23439006
Coinhibitory molecules in cancer biology and therapy., PMID:23380546
Application of monoclonal antibodies in a sandwich enzyme-linked immunosorbent assay for identification and detection of soluble human B and T lymphocyte attenuator., PMID:23244320
For research use only. Not for human or drug use.
